ReviewAmerican journal of cancer research2018

A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approach.

Anita Gul et al.PubMed ↗Full text ↗

No numbers read from the abstract.